OBJECTIVES: I. Compare the response of previously untreated patients with chronic inflammatory demyelinating polyneuropathy to intravenous immune globulin vs. placebo.
PROTOCOL OUTLINE: This is a randomized, double-blind study. The first group receives intravenous immune globulin (IVIG) on days 1, 2, and 21; the second group receives an intravenous placebo on the same schedule. Patients in either group may receive IVIG (same dosage as first group) after day 42. Concurrent steroids and other immune globulin preparations are prohibited.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
90
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.